afuresertib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl
  • InChIKey: AFJRDFWMXUECEW-LBPRGKRZSA-N
  • Mol. Mass: 427.33
  • ALogP: 3.89
  • ChEMBL Molecule:
    afuresertib  
More Chemistry

Pharmacology

Alternative names

afuresertib | gsk2110183 | gsk2110183c | gsk21110183

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Breast Neoplasms (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Endometrial Neoplasms (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1/Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Uterine Cervical Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 20
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue